| Features: | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Copper Metal Copper levels are considerably elevated in various malignancies. Copper [Cu(II)] is a transition and trace element in living organisms. It increases reactive oxygen species (ROS) and free-radical generation that might damage biomolecules like DNA, proteins, and lipids. RDA: 900 mcg, ULs: 10,000mcg Copper (dietary/physiology) ≠ copper-loading therapeutics ≠ copper nanoparticles. For Cu nanoparticles, the dominant and most reproducible theme is toxicity via ROS → mitochondrial damage/genotoxicity, not clean tumor selectivity. - Copper acts as a critical cofactor for numerous enzymes involved in redox reactions, energy production, and connective tissue formation. - Increased copper levels in the tumor microenvironment can enhance angiogenic signaling and thus supply the tumor with necessary oxygen and nutrients, facilitating tumor growth and metastasis. - Copper can participate in redox cycling reactions, similar to the Fenton reaction, leading to the production of reactive oxygen species (ROS). - Cancer cells often exhibit altered copper homeostasis, with some studies showing elevated copper levels in tumor tissues relative to normal tissues. Copper serves a dual role in cancer: Imbalanced copper metabolism promotes tumor cell proliferation and survival by activating the receptor tyrosine kinase, PI3K/Akt/mTOR, and MAPK/ERK signaling pathways, while cuproptosis suppresses tumor growth by inducing cell death and activating immune responses Two main approaches are: - Copper Chelation: Drugs that bind copper (chelators) can reduce the bioavailability of copper, potentially inhibiting angiogenesis and other copper-dependent tumor processes. - Copper Ionophores: These agents facilitate the transport of copper into cancer cells to induce cytotoxicity by elevating intracellular copper levels beyond a tolerable threshold, leading to cell death. - Depletion of glutathione and stimulation of lipid peroxidation, catalase and superoxide dismutase. - Studies have shown that the level of copper in tumour cells and blood serum from cancer patients is elevated, and the conclusion is that cancer cells need more copper than healthy cells. (but also sometimes depleted). - Copper is a double-edged sword, maintaining normal cell development and promoting tumor development. - Tumor tissue has a higher demand for copper and is more susceptible to copper homeostasis, copper may modulate cancer cell survival through reactive oxygen species (ROS) excessive accumulation, proteasome inhibition and anti-angiogenesis. Copper and Cu NanoParticles — Copper is an essential redox-active trace metal and transition element that becomes oncology-relevant through copper homeostasis, copper-dependent enzymes, copper chelation, copper ionophore/copper-loading strategies, and copper-based nanoparticles. The formal classification is mixed: elemental/ionic metal biology, copper coordination chemistry, micronutrient/mineral exposure, and inorganic/nano-oncology modality. Standard abbreviations include Cu, Cu(I), Cu(II), CuNP, CuO-NP, Cu2O-NP, DSF/Cu, and TM for tetrathiomolybdate. The most important distinction is that dietary copper physiology, therapeutic copper depletion, copper ionophore loading, copper complexes, and copper nanoparticles are not interchangeable exposures. Primary mechanisms (ranked):
Bioavailability / PK relevance: Oral nutritional copper is normally tightly regulated by absorption, biliary excretion, ceruloplasmin binding, and intracellular chaperones. Copper nanoparticles and copper oxide nanoparticles have distinct PK and toxicology constraints because particle size, coating, dissolution, route of exposure, aggregation, and organ deposition can dominate exposure. Copper chelation requires systemic copper lowering, while copper-loading strategies require sufficient intracellular Cu delivery without unacceptable normal-tissue toxicity. In-vitro vs systemic exposure relevance: Many CuNP/CuO-NP anticancer experiments use direct cell-culture concentrations that may exceed safe or achievable systemic exposure and may reflect non-selective cytotoxicity. For ionic copper, free copper concentrations in vivo are extremely buffered, so simple CuSO4 or CuCl2 in-vitro experiments do not map cleanly onto physiological free copper. For DSF/Cu and copper complexes, exposure relevance depends on complex formation, albumin/protein binding, tumor delivery, and copper transporter state. Clinical evidence status: Copper biology is strongly supported mechanistically. Copper chelation has small human and phase II evidence, mainly as an anti-angiogenic or microenvironment strategy, but is not established standard oncology care. DSF/Cu has phase I/II and randomized clinical evidence in glioblastoma; the recurrent glioblastoma randomized trial did not show survival benefit and reported increased toxicity. CuNP/CuO-NP anticancer claims remain predominantly preclinical, with major translation constraints from oxidative, hepatic, renal, inflammatory, genotoxic, and mitochondrial toxicity signals. Interpretation note: Copper biology and copper nanoparticles should not be treated as equivalent exposures. Ionic copper, nutritional copper, copper chelation, copper ionophores, copper complexes, CuNPs, CuO-NPs, and Cu2O-NPs differ in pharmacokinetics, intracellular copper delivery, redox behavior, biodistribution, and toxicity. Directional tags such as ROS↑, angiogenesis↑/↓, GSH↓, NRF2↑/↓, and chemosensitization should be interpreted according to exposure class. Copper Cancer Mechanism Table
Time-Scale Flag (TSF): P / R / G
Copper Nanoparticles: CuNP / CuO-NP (tox + “anticancer” claims are mostly preclinical) Copper Nanoparticle Cancer Mechanism Table
Time-Scale Flag (TSF): P / R / G
|
| Source: |
| Type: |
| Tumor cell invasion is a critical process in cancer progression and metastasis, where cancer cells spread from the primary tumor to surrounding tissues and distant organs. This process involves several key steps and mechanisms: 1.Epithelial-Mesenchymal Transition (EMT): Many tumors originate from epithelial cells, which are typically organized in layers. During EMT, these cells lose their epithelial characteristics (such as cell-cell adhesion) and gain mesenchymal traits (such as increased motility). This transition is crucial for invasion. 2.Degradation of Extracellular Matrix (ECM): Tumor cells secrete enzymes, such as matrix metalloproteinases (MMPs), that degrade the ECM, allowing cancer cells to invade surrounding tissues. This degradation facilitates the movement of cancer cells through the tissue. 3.Cell Migration: Once the ECM is degraded, cancer cells can migrate. They often use various mechanisms, including amoeboid movement and mesenchymal migration, to move through the tissue. This migration is influenced by various signaling pathways and the tumor microenvironment. 4.Angiogenesis: As tumors grow, they require a blood supply to provide nutrients and oxygen. Tumor cells can stimulate the formation of new blood vessels (angiogenesis) through the release of growth factors like vascular endothelial growth factor (VEGF). This not only supports tumor growth but also provides a route for cancer cells to enter the bloodstream. 5.Invasion into Blood Vessels (Intravasation): Cancer cells can invade nearby blood vessels, allowing them to enter the circulatory system. This step is crucial for metastasis, as it enables cancer cells to travel to distant sites in the body. 6.Survival in Circulation: Once in the bloodstream, cancer cells must survive the immune response and the shear stress of blood flow. They can form clusters with platelets or other cells to evade detection. 7.Extravasation and Colonization: After traveling through the bloodstream, cancer cells can exit the circulation (extravasation) and invade new tissues. They may then establish secondary tumors (metastases) in distant organs. 8.Tumor Microenvironment: The surrounding microenvironment plays a significant role in tumor invasion. Factors such as immune cells, fibroblasts, and signaling molecules can either promote or inhibit invasion and metastasis. |
| 6182- | Cu, | Role of cuproptosis in digestive system tumors (Review) |
| - | Review, | Var, | NA |
Query results interpretion may depend on "conditions" listed in the research papers. Such Conditions may include : -low or high Dose -format for product, such as nano of lipid formations -different cell line effects -synergies with other products -if effect was for normal or cancerous cells
Filter Conditions: Pro/AntiFlg:% IllCat:% CanType:% Cells:% prod#:64 Target#:324 State#:% Dir#:2
wNotes=0 sortOrder:rid,rpid